ROIV — Roivant Sciences Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1635088 ·
United Kingdom
Last close
$38.71
Market Cap
$28.05B
52W High
$42.50
52W Low
$19.96
ADV30
7,733,231
Next earnings
2027-02-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 35,121,000 | 31,774,000 | -268,049,000 | -191,619,000 | 4,975,824,000 | — | 4,975,824,000 |
| Jun 2026 | 1,442,000 | 1,158,000 | -366,385,000 | -189,837,000 | 5,306,493,000 | 1,248,456,000 | 384,624,000 |
| Mar 2026 | 2,520,000 | 2,200,000 | -354,995,000 | 302,994,000 | 5,708,687,000 | 1,419,232,000 | 416,275,000 |
| Dec 2025 | 1,999,000 | 1,299,000 | -339,153,000 | -265,891,000 | 5,225,368,000 | 1,478,270,000 | 251,144,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,388,000
Investing CF
$606,760,000
Financing CF
$-171,307,000
CapEx
$-9,736,000
Dividends Paid
—
Buybacks
$-392,413,000
EPS Diluted TTM
$-0.63
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,164,473,000
Inventory
—
Receivables
$771,627,000
ST Investments
$2,593,626,000
EBIT TTM
$-1,328,582,000
Pretax Income TTM
$-297,181,000
Interest Exp TTM
—
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$41,082,000
EBITDA
$-1,322,877,952
Free Cash Flow
$-358,864,864
Enterprise Value
$25,116,303,360
Total Cash
$4,207,586,048
Total Debt
$106,570,000
Shares Out
724,561,460
Trailing EPS
$-0.65
Book Value
$5.55
ROE
-8.5%
ROA
-16.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,260,000 | -1,285,303,000 | -299,771,000 | 5,708,687,000 | 416,275,000 | 4,527,370,000 | -750,349,000 |
| Mar 2025 | 29,053,000 | -1,113,681,000 | -171,981,000 | 5,436,940,000 | 249,742,000 | 4,687,605,000 | -839,451,000 |
| Mar 2024 | 32,713,000 | -824,928,000 | 4,348,926,000 | 7,222,482,000 | 773,953,000 | 5,968,581,000 | -765,268,000 |
| Mar 2023 | 31,530,000 | -809,014,000 | -1,009,030,000 | 2,389,604,000 | 782,017,000 | 1,157,766,000 | -843,393,000 |
TTM Snapshot
Revenues TTM
$7,532,000
NetIncome TTM
$-266,253,000
OpCashFlow TTM
—
Assets (Latest)
$5,306,493,000
Forward EPS
$-1.61
Max Pain — expiry 2026-12-18
max pain strike: $37.00 · spot: $38.73 · call oi: 21,051 · put oi: 12,829
Expected Move to 2026-12-18:
±$6.88
(17.75%) —
implied range
$31.85 –
$45.60
· ATM straddle on $39.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INSM | INSMED Inc | $26.73B | $121.86 | — |
| RPRX | Royalty Pharma plc | $30.58B | $68.68 | — |
| UTHR | UNITED THERAPEUTICS Corp | $24.88B | $584.10 | — |
| GMAB | GENMAB A/S | $31.95B | $51.96 | — |
| VTRS | Viatris Inc | $23.45B | $20.45 | — |
News headlines (Yahoo Finance, 1h cache)
How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)
2026-11-12 07:14 · Yahoo
Roivant Sciences Ltd (ROIV) (Q2 2026) Earnings Call Highlights: LISRIA Launch Delivers $31 ...
2026-11-10 09:02 · Yahoo
Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript
2026-11-09 22:13 · Yahoo
Roivant Sciences Q2 Earnings Call Highlights
2026-11-09 17:15 · Yahoo
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
2026-11-09 12:40 · Yahoo
Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value
2026-11-05 06:13 · Yahoo
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
2026-10-23 17:25 · Yahoo
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
2026-10-21 15:04 · Yahoo
Roivant Sciences stock surges on positive uveitis trial data
2026-10-21 13:09 · Yahoo
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
2026-10-21 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.